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Introduction: Estrogen forms a complex with the estrogen receptor (ER) that binds to estrogen response elements
(EREs) in the regulatory region of estrogen-responsive genes and regulates their transcription. Sequence variants in the
regulatory regions have the potential to affect the transcription factor–regulatory sequence interaction, resulting in
altered expression of target genes. This study explored the association between single-nucleotide polymorphisms
(SNPs) within the ERE-associated sequences and breast cancer progression.
Methods: The ERE-associated sequences throughout the whole genome that have been demonstrated to bind
ERα in vivo were blasted against online information from SNP data sets and 54 SNPs located adjacent to
estrogen-responsive genes were selected for genotyping in two independent cohorts of breast cancer patients:
779 patients in the initial screening stage and another 888 in the validation stage. Deaths due to breast cancer
or recurrence of breast cancer were defined as the respective events of interest, and the hazard ratios of
individual SNPs were estimated based on the Cox proportional hazards model. Furthermore, functional assays
were performed, and information from publicly available genomic data and bioinformatics platforms were used
to provide additional evidence for the associations identified in the association analyses.
Results: The SNPs at 21q22.3 ERE were significantly associated with overall survival and disease-free survival of
patients. Furthermore, these 21q22.3 SNPs (rs2839494 and rs1078272) could affect the binding of this
ERE-associated sequence to ERα or Rad21 (an ERα coactivator), respectively, which resulted in a difference in
ERα-activated expression of the reporter gene.
Conclusion: These findings support the idea that functional variants in the ERα-regulating sequence at 21q22.3
are important in determining breast cancer progression.Introduction
The roles of estrogen receptor α (ERα) in initiating
tumor development in breast cancer, regulating progres-
sion and determining therapeutic protocols and efficacy
are well documented [1,2]. However, not all patients
with the same ERα status manifest the same cancer pro-
gression or response to hormone therapy, and individual* Correspondence: bmcys@ibms.sinica.edu.tw
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unless otherwise stated.variations in breast cancer progression have remained an
issue of particular concern. Although ERα can be activated
in an estrogen-independent manner, the classical activa-
tion mechanism involves the binding of ERα to estrogen
and other coactivator proteins to form the estrogen-
bound ER complex, which functions as a transcriptional
regulator [3,4]. The DNA-binding domain of ERα binds to
estrogen response elements (EREs) in the regulatory re-
gion of estrogen-responsive genes, activating or repressing
their transcription and consequently mediating physio-
logical or tumorigenic effects. Since sequence variants,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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in the regulatory regions of genes have the potential to
affect protein (transcription factor)–DNA (regulatory re-
gion) interactions, resulting in altered expression of target
genes [5,6]. We previously examined the hypothesis that
genetic variations of genome-wide EREs might be associ-
ated with breast cancer development, and we identified a
significant effect of several ERE-associated SNPs on breast
cancer risk [7]. However, because the ERE sites we exam-
ined were based on prediction by a computational algo-
rithm and lacked confirmation by results from cell-based
assays, it was not possible to know whether such EREs in-
deed function as predicted in vivo. In the present study,
we explored the association between genetic variants
within these ERE-associated sequences and breast cancer
progression. Importantly, these ERE-associated sequences
scattered throughout the whole genome have been shown,
by using chromatin immunoprecipitation (ChIP)–based
methods, to bind ERα in vivo [8-10]. This is a promising
approach for identifying the breast tumorigenic contribu-
tion of EREs on a genome-wide scale. Furthermore, we
performed functional assays and used information from
publicly available genomic data and bioinformatics plat-
forms to provide additional evidence for the association
identified in the association analysis. The results obtained
by the combined use of these different approaches in this
multistage study support the idea that functional variants
in the ERα-regulating sequence at 21q22.3 are important
in determining breast cancer progression.
Methods
Study participants
Two independent cohorts of patients with incident pri-
mary breast cancer, 779 of whom were in the initial
screening stage and another 888 in the validation stage
(Figure 1A), were included in the present study. All of
the patients were part of our ongoing cooperative study
aimed at understanding the causes and progression of
breast cancer in Taiwan. Their characteristics have been
described in detail elsewhere [7,11-13]. Two independent
groups of women without a history of cancer were re-
cruited. One of these groups comprised 870 women from
the same source as the patients in the initial screening
phase. That group was used as the control group to ex-
plore the association between SNPs and breast cancer
development. The other group comprised 903 women
chosen from the National Biobank of Taiwan [14]; we used
their data to provide background information about
haplotype block and linkage disequilibrium (LD) between
SNPs in our population.
This study was approved by the ethics committee of
the institutional review board of the Academia Sinica,
Taiwan, and informed consent was obtained from allstudy participants before the collection of data by
personal interview.
Single-nucleotide polymorphisms and genotyping
Genome-wide EREs were detected by ChIP using anti-
ERα antibodies in different ERα-positive breast cancer
cells [8-10]. These ERE sites were blasted against the
SNP database, resulting in the identification of the ERE-
associated SNPs. Multiple steps were used to select the
SNPs for genotyping; these steps are described in the
Results section. In the initial screening stage, SNPs were
genotyped in all samples tested using Sequenom iPLEX
technology (Sequenom, Hamburg, Germany). Duplicate
positive and negative controls were included on all plates,
with genotypes autocalled by using specialized software
(MassARRAY Typer version 3.4; Sequenom) and subse-
quently confirmed by visual assessment of the data. All as-
says were performed by individuals blinded to the case
versus control status of the samples. As a quality control,
we repeated the genotyping on 10% of the samples, and all
genotype scoring was performed and checked separately
by one reviewer who was unaware of the case versus con-
trol status. The concordance rate for replicate samples
was 100%. In the validation stage, the genotyping data at
specific SNPs for 888 patients with incident breast cancer
were used. These SNPs showed strong LD with those sig-
nificant SNPs identified in the initial screening stage. These
888 patients had been included in the international Collab-
orative Oncological Gene-environment Study (COGS), in
which genotyping was performed using a customized
Illumina Infinium BeadChip array (Illumina, San Diego,
CA, USA) [15,16]. Using the National Biobank of
Taiwan, a total of 642,832 SNPs from 903 women were
genotyped, and the details of the SNPs, how they were
selected and the genotyping results are publicly avail-
able on the Taiwan Biobank website [14].
Statistical analysis
To identify putative high-risk genotypes of ERE-associated
SNPs for breast cancer incidence in the initial screening
stage, we followed our previously established sequential
steps [7,11-13] to analyze the data. Hardy-Weinberg equi-
librium was tested to ensure that the chance of genotyping
error was small. Logistic regression was used to estimate
the odds ratio of breast cancer associated with harboring
an individual genotype. Data on ERα status (positive or
negative), histologic grade (well-differentiated to poorly
differentiated) and clinical stage (I to IV) were collected
from hospital medical records. We were thereby able to
determine whether an ERE-associated SNP influenced
prognosis. To this end, we calculated the overall survival
(OS) rate and the breast cancer–specific survival rate (that
is, disease-free survival (DFS)) using the Kaplan-Meier
method and the two-tailed logrank test, with death due to
Figure 1 Identification and functional examination of genome-wide estrogen response element–associated single-nucleotide polymorphisms
associated with breast cancer progression. (A) Flow diagram showing the sequential steps in the present study. (B) Selection of single-nucleotide
polymorphisms (SNPs) to be genotyped. SNPs located within regions that bind estrogen receptor α (ERα) in vivo were selected, and then they were
examined for whether they were located within the regions 10 kb 3′ or 10 kb 5′ of known estrogen (estradiol (E2))-responsive genes. As a result, after
excluding those that could not be genotyped by using the iPLEX platform, 46 estrogen response element (ERE)–associated SNPs were genotyped. ChIP,
Chromatin immunoprecipitation; DFS, Disease-free survival; OS, Overall survival.
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the respective event of interest. In addition, the hazard
ratios (HRs) of individual SNPs associated with OS or
DFS were estimated based on the Cox proportional
hazards model, considering the effect of the patients’
age, ER status and cancer stage. All statistical analyses
were performed using SAS version 9.1 software (SAS
Institute, Cary, NC, USA), and all tests were based on
a two-sided probability. To address the issue of false-
positivity due to multiple tests, a permutation test [17]
was performed when needed.
LD plots of the D’ values for SNPs within the same
haplotype block were produced using the Haploview
program [18]. Haplotype estimation was performed on
individuals for whom complete genotype data were
available across all polymorphic sites, and the highest
probability haplotypes, estimated using the expectation
maximization algorithm of SAS Genetics 9.1 (SAS Institute),
were assigned to each study participant [19].
Sequencing
Sanger sequencing was performed to detect single-
nucleotide variants within specific genomic regions.
Cell culture
The human breast cancer cell line MCF-7 was pur-
chased from the Taiwan Bioresource Collection and
Research Center. The cells were cultured in Dulbecco’s
modified Eagle’s medium (Sigma-Aldrich, St Louis, MO,
USA), supplemented with 10% fetal bovine serum
(Gibco, Grand Island, NY, USA).Construct generation, transfection and site-directed
mutagenesis
The ERα-binding regions containing specific ERE-associated
SNPs were amplified by PCR from human genomic DNA
and inserted into the promoter region of the pGL3-Basic
vector (Promega, Madison, WI, USA) at the NheI-XhoI
restriction site. ERα- and Rad21-expressing constructs
were amplified from cDNA. The former were cloned into
the EcoRI-XhoI sites, and the latter into the NotI-XhoI
sites, of the mammalian expression vector pcDNA3-Flag.
For site-directed mutagenesis, specific point mutations
(that is, variant alleles) were generated using Quik-
Change Site-Directed Mutagenesis kits (Stratagene/
Agilent Technologies, Santa Clara, CA, USA) according
to the manufacturer’s instructions. Transfection of
plasmids was performed using Lipofectamine 2000
reagent (Invitrogen, Carlsbad, CA, USA) according to the
manufacturer’s instructions.Luciferase reporter assay
The luciferase constructs and pRL-TK, which encodes
Renilla luciferase, were cotransfected into 5 × 104 MCF-7
cells in 24-well plates. After 48 hours, the cells were
lysed in a single freeze–thaw cycle in passive lysis buffer.
The lysate was then centrifuged at 12,000 g for 10 mi-
nutes at 4°C, and the luciferase activities in the super-
natant were measured using Dual-Luciferase Reporter
Assay System kits (Promega). The relative activity of lu-
ciferase was determined using the Renilla luciferase
signal as the reference.
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ChIP was performed based on our previous protocol
[20] using EZ-Magna ChIP G kits (EMD Millipore,
Billerica, MA, USA) following the manufacturer’s in-
structions and using anti-Flag monoclonal antibody
(F3165; Sigma-Aldrich) for the precipitation stage. The
immunoprecipitate was eluted with 50 μl of the supplied
Tris-ethylenediaminetetraacetic acid buffer, and 2 μl of
DNA were used in quantitative PCR (qPCR). The primer
pairs used for the ChIP PCR were 5′-CCGGCCATCTCTC
ACTATGAA-3′ and 5′-CCTTCCCGCCAGGGTAAATA
C-3′ for TFF1 and 5′-CTTGAGGTGCTTCGAGACAGT
G-3′ and 5′-CACCTGCTTCAAAGTGAGTGAG-3′ for
21q22.3.
Results
Characteristics of the patient cohorts
The risk profile of breast cancer in our study partici-
pants was similar to that found in our previous studies
[11-13] and in other breast cancer studies [21]. Develop-
ment of breast cancer was found to be highly associated
with reproductive risk factors, including early menarche
(adjusted odds ratio (aOR), 1.33; 95% confidence interval
(CI), 1.09 to 1.64), nulliparity (aOR, 1.37; 95% CI, 1.03 to
1.85), low number of full-term pregnancies (less than
two) (aOR, 1.12; 95% CI, 0.89 to 1.40) and no history of
breastfeeding (aOR, 1.49; 95% CI, 1.21 to 1.83). Import-
antly, these significant associations between reproductive
risk factors and breast cancer reveal the importance of
the estrogen-related etiology of breast cancer in our par-
ticipants, providing us with the opportunity to examine
the contribution of EREs during breast tumorigenesis.
Because the present study was focused on SNPs in ERE-
associated sequences involved in determining breast can-
cer progression, we also examined factors in the clinical
profile that correlated with OS and DFS. As expected,
patient age at tumor onset, ER status and tumor stage
were three major determinants in our cohort and were
included in all of our analyses so that we could examine
the effect of SNPs on breast cancer progression.
Selection of estrogen response element–associated
single-nucleotide polymorphisms for genotyping
Genome-wide ERα-binding sites have previously been de-
tected using ChIP-based methods [8-10], and more than
1,500 binding regions have been identified. After blasting
these regions against online information available from
SNP data sets (UCSC Genome Browser, National Center
for Biotechnology Information and HapMap databases),
including more than 38 million SNPs throughout the
whole genome, more than 750 SNPs were identified in
ERα-associated sequences (Figure 1B). We next examined
whether these SNPs were located adjacent to estrogen-
responsive genes, as genetic variants near genes may affectthe interactions of transcription factors with the pro-
moter/enhancer/regulatory regions, resulting in altered
mRNA expression. To do so, we used the bioinformatics
tool GenePipe [22] to screen for SNPs located within the
regions 10 kb 3′ or 10 kb 5′ of estrogen-responsive genes,
identified by showing a significant change in expression
when the ERα-positive breast cancer cells were treated
with estrogen [8-10]. Taking statistical power consider-
ations into account, we included only SNPs with a minor
allele frequency greater than 5% in the Chinese popula-
tion. As a result, 54 SNPs were identified, and, after ex-
cluding 8 that could not be genotyped in the iPLEX
platform, a total of 46 SNPs were genotyped in all patients
and controls in the initial screening stage (Figure 1A).
Identification of single-nucleotide polymorphisms associated
with breast cancer development and progression
We next sought to determine the breast tumorigenic con-
tribution of ERE-associated SNPs. In the initial screening
stage, we examined whether the genotypic distribution of
these 46 SNPs differed between cases and controls and be-
tween cases with different progression outcomes (that is,
OS versus DFS) (Figure 1A). The frequencies of all SNPs
in the controls agreed with those expected on the basis of
the Hardy-Weinberg equilibrium, suggesting that genotyp-
ing errors were relatively unlikely. The results for the
genotypic analysis showed that nine SNPs were associated
with breast cancer incidence (Figure 2A and 2B, left panel)
and that eleven SNPs were associated with survival (DFS
or OS) (Figure 2A and 2B, center and right panels).
Women carrying the homozygous variant genotype had a
significantly increased aOR or HR (P <0.05) compared to
women carrying the homozygous and heterozygous wild-
type genotypes. The possibility of false-positives due to
multiple testing is relatively unlikely, because the results of
the permutation test [17], based on 10,000 random per-
mutations, showed that these associations were significant
(data not shown). Particular attention was focused on four
SNPs, each of which was associated with both breast can-
cer incidence and progression (Figures 1A, 2A and 2B).
Though the genetic variants associated with cancer pro-
gression are not necessarily those associated with cancer
incidence, variants that play a dual role in different stages
during tumorigenesis are certainly of more tumorigenic
importance. Of these four SNPs, two (rs2839494 and
rs1078272) are located in the same LD block at 21q22.3
and the other two at 5p12 and 20q13.2 (Figure 2A).
Validation of 21q22.3 single-nucleotide polymorphisms
for breast cancer progression
To confirm the significant associations between specific
ERE-associated SNPs and breast cancer progression de-
tected in the initial screening, we studied an independ-
ent cohort of 888 breast cancer patients (Figure 1A).
Figure 2 Estrogen response element–associated single-nucleotide polymorphisms related to breast cancer incidence and progression.
Genomic sites (A) and adjusted odds ratios (aORs), hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) (B) of the estrogen
response element (ERE)–associated single-nucleotide polymorphisms (SNPs) found to be significantly associated with breast cancer incidence
(left panel), overall survival (OS; center panel) or disease-free survival (DFS; right panel). Known genes adjacent to these SNPs are shown in gray in
(A). aORs were estimated by logistic regression analyses, and the HRs were estimated by applying the Cox proportional hazards model. In total,
779 patients (106 deaths and 126 cases with breast cancer recurrence during follow-up) and 870 controls were included in these analyses.
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ported in the COGS genome-wide association study
(GWAS) [15,16]. We first validated that the SNPs at 5p12,
20q13.2 and 21q22.3, genotyped in our COGS patients,
were in very strong LD (all LD coefficients between
SNPs >0.95 in our population) with the four significant
SNPs identified in our initial screening, not only in Han
Chinese using HapMap data but also in Taiwanese women
using Taiwan Biobank data [14]. These SNPs were then
tested for their associations with cancer progression.
The polymorphic status of 21q22.3, now reflected by
rs2251362 (Figure 3A), remained significantly associated
with OS and DFS in the validation stage (Figure 4A). Moreimportantly, to examine whether an ERα-associated
mechanism could explain this association, we stratified
our patients based on the ER status of their tumors
and found that the significant association between
rs2251362 and cancer progression was present only in
the ERα-positive patients (Figure 4A). These results
prompted us to retrospectively check the interaction
between 21q22.3 SNPs and the ER in the patients included
in the initial screening. Consistent with the finding
above, the association between breast cancer progression
(indicated by OS) and ERE-associated SNP at 21q22.3
(that is, rs1078272) was more significant in patients
harboring specific genotypes of a SNP (rs985694) of ESR1,
Figure 3 Schematic diagrams of the 21q22.3 block and the 21q22.3 region that binds estrogen receptor α. (A) Three single-nucleotide
polymorphisms (SNPs) were found to be significantly associated with breast cancer progression, of which two (rs2839494 and rs1078272) were
associated with estrogen response elements (EREs) and located at a region that binds estrogen receptor α (ERα). These two SNPs were used in
the initial screening stage, and rs2251362 was used in the validation stage. Two additional SNPs, rs2839500 and rs2839501, were exonic SNPs
detected by direct sequencing of the 21q22.3 block (see text for details). All five SNPs are located in the same 21q22.3 haplotype block. The
linkage disequilibrium (LD) plot shows LD between the SNPs in 21q22.3 in Han Chinese women. The strength of the LD between SNPs, indicated
by the color scheme, was measured using a combination of the statistic D′ and the logarithm of odds (LOD) score (dark red shading, D′ =1 and
LOD score ≥2; light red shading, D′ <1 and LOD score ≥2). (B) Top panel: The 21q22.3 block (yellow) and the 21q22.3 region to which ERα binds
(gray). Middle panel: Enlarged view showing the half-ERE sites (thin gray bars), exons (red) and untranslated regions (blue) of TMPRSS3/TFF1, and the
regions to which ERα and the ER coactivator Rad21 bind, detected by using the Encyclopedia of DNA Elements (ENCODE). Bottom panel: The 21q22.3
region to which ERα binds. The major and minor alleles of the three SNPs in this region are indicated. ChIP, Chromatin immunoprecipitation.
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haplotype analysis in which a polymorphism of 21q22.3
was defined more precisely by the two ERE-associatedSNPs rs2839494 and rs1078272. As shown in Figure 4C,
women carrying the haplotype pair of the variant allele
of both rs2839494 and rs1078272 (Vt-Vt/Vt-Vt) were
Figure 4 Associations between single-nucleotide polymorphisms in 21q22.3 in tumors displaying different estrogen receptor status
and breast cancer progression. (A) The 21q22.3 single-nucleotide polymorphism (SNP) rs2251362 is significantly associated with both overall
survival (OS) and disease-free survival (DFS) in all patients, especially in estrogen receptor–positive (ER+) patients, as detected in the validation
stage. Hazard ratios (HRs) and 95% confidence intervals (95% CIs) were estimated based on the Cox proportional hazards model, considering the
effects of the patients’ age, ER status and cancer stage. A total of 888 breast cancer patients (39 deaths and 33 patients with breast cancer
recurrence during follow-up) were included. (B) The association between genetic polymorphism of the estrogen response element (ERE)–associated
SNP in 21q22.3 (defined by rs1078272) and OS was significantly modified by the genotype of the SNP (that is, rs985694) of ESR1, the gene encoding
the ER. (C) Association between genetic polymorphism of 21q22.3 detected by the haplotype pairs containing the two ERE-associated SNPs (rs2839494
and rs1078272) and OS of breast cancer patients with ER + tumors (left panel) or ER − tumors (right panel). The 779 patients (106 deaths and 126
patients with breast cancer recurrence during follow-up) in the initial screening were included in the analyses depicted in (B) and (C). HRs and 95% CIs
were estimated based on the Cox proportional hazards model, considering the effects of the patients’ age and cancer stage.
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those carrying other haplotype pairs, particularly in the
ER-positive patients.
Functional examination of the two estrogen response
element–associated single-nucleotide polymorphisms
at 21q22.3
On the basis of the above-described results, functional
studies were performed to examine the effect of these two
ERE-associated SNPs at 21q22.3 (Figure 1A). As shown in
Figure 3B, rs2839494 and rs1078272 are located in an
ERα-binding segment spanning 803 bp, containing three
half-ERE sequences and covering exon 10 of TMPRSS3. In
addition, at a region 9.5 kb 5′ of this segment, there is a
gene, TFF1, which has been shown to be a suppressor of
breast cancer in a mouse model [23]. We first demon-
strated estradiol (E2)-dependent regulatory activity of this
803-bp segment by an E2 dose-dependent increase in re-
porter gene activity when the segment was linked to the
luciferase reporter gene, the construct transfected into ER-
positive MCF-7 cells and the transfected cells incubated
with increasing levels of E2 (Figure 5A). To examine
the effect of the variant alleles on transcription and to
differentiate the effects of rs2839494 and rs1078272, wegenerated one variant allele of each SNP by mutating the
wild type and tested their individual effects in regulating re-
porter gene activity. Each of the variant alleles led to signifi-
cantly decreased luciferase activity (Figure 5B). However,
interestingly, the two variant alleles resulted in different
phenotypes with decreased ERα-regulated activity. The vari-
ant allele of rs2839494 completely abolished the response
to E2, and the variant allele of rs1078272 decreased the
response but maintained the dose–response relationship
between E2 and reporter gene activity. This marked differ-
ence suggested different inhibition mechanisms (Figure 5C),
which were examined in our following experiments.
Direct sequencing to search for additional
single-nucleotide polymorphisms within 21q22.3
To gain support for a causal role of these two ERE-
associated SNPs (rs2839494 and rs1078272) in 21q22.3,
we attempted to clarify alternative possibilities, including
that (1) rs2839494 and rs1078272 might be in LD with an
exon change in TMPRSS3 that affects protein function, (2)
other changes in this 21q22.3 block might be within regu-
latory sequences and affect the level of expression through
transcriptional regulation and (3) alterations in other adja-
cent genes might increase susceptibility to breast cancer
Figure 5 Functional examination of the two estrogen response element–associated single-nucleotide polymorphisms rs2839494 and
rs1078272 in 21q22.3. (A) Activity in MCF-7 cells of the luciferase reporter gene, either alone (denoted as “No promoter”) or linked to the
21q22.3 region (that is, the segment shown in Figure 3B, bottom panel) to which estrogen receptor α (ERα) binds, and which contains the two
estrogen response element (ERE)–associated single-nucleotide polymorphisms (SNPs) (denoted as “21q22.3”), in the presence or absence of
estradiol (E2). (B) Decreased activity of the luciferase reporter gene in MCF-7 cells when linked to the 21q22.3 region harboring the variant allele
(VT) of rs2839494 or rs1078272 compared to that containing both wild-type alleles (WT). The results shown in (A) and (B) are means ± standard
deviations (n = 3). The P-values of differences between groups and the P-values for trends within groups were estimated by regression analysis.
(C) Hypothetical model explaining the similar, but not identical, effects of the two ERE-associated SNPs at 21q22.3, showing that the variant allele
of rs1078272 might block the binding of a coactivator to the 21q22.3 sequence (bottom panel), whereas the variant allele of rs2839494 might directly
affect the binding of ERα (center panel), both decreasing reporter gene activity compared to the wild-type 21q22.3 sequence (top panel).
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21q22.3 block (Figure 3A and 3B, top panel), the third
possibility is unlikely. To examine the first possibility,
using blood specimens from 100 healthy individuals, we
performed exonic sequencing of all TMPRSS3 exons
within this block and identified three SNPs: rs2839500,
rs2389501 and rs113747896 (Figure 3A and 3B, bottom
panel; and Table 1). None of these SNPs are novel; the first
two have been shown to have no pathogenic effect [24,25],
and the third, located within exon 10 of TMPRSS3, results
in no amino acid change (D374D) (Figure 3B and
Table 1). To examine the second possibility listed above,
using blood specimens from 58 healthy individuals, we
performed direct sequencing to identify any variants
within this 21q22.3 block containing 9,940 bp (Table 1).
We found that some of the identified SNPs were located
at transcription factor binding sites, so we cannot totallyTable 1 Direct sequencing of the 21q22.3 block to identify sin
Base pairs Half-ERE sites SNPsb (n) Novel
SNPsb (n
21q22.3 block 9,940 17 37 6
ERα-binding sequence
within 21q22.3
803 3 3 0
aChIP, Chromatin immunoprecipitation; ERα, Estrogen receptor α; ERE, Estrogen resp
N, the number of nucleotide. bBased on HapMap CHB (Han Chinese in Beijing, Chin
The novel SNPs were identified by the sequencing of 58 individuals. cBased on Hap
individuals, no exonic SNP was identified. dBased on Encyclopedia of DNA Elements
ERα-binding sequence showed no evidence of ERα binding.exclude the possibility that these variants affect expres-
sion of E2/ERα-regulating genes. However, it is notable
that the 803-bp ERE-associated sequence was the only
segment within the 21q22.3 block that could bind ERα
(Table 1). As a result, rs2839494 and rs1078272 appear
to be candidate causal variants.
Bioinformatics and functional evidence that the
Rad21-coactivated E2-induced increase in promoter
activity is affected by ERE-associated SNPs in 21q22.3
It is notable that Encyclopedia of DNA Elements (EN-
CODE) data [26] show that rs2839494 and rs1078272
lie, respectively, within different binding regions of ERα
and Rad21, a coactivator of ERα [27]. Given the differ-
ence in phenotype of the effect on E2-dependent regula-
tory activity between rs2839494 and rs1078272 (shown










3 0 10 Only the one below
1 0 2 Yes
onse element; SNP, Single-nucleotide polymorphism; TF, Transcription factor;
a), dbSNP137 and direct sequencing of blood specimens from 58 individuals.
Map CHB, dbSNP137 and exonic sequencing of blood specimens from 100
(ENCODE). The eight SNPs within the TF binding sites but outside the
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action of transcription factors with promoter/enhancer/
regulatory regions) by different mechanisms (Figure 5C).
On the basis of the ENCODE data, rs1078272 is located
within the segment bound by Rad21, and the variant allele
might affect the binding of Rad21 to the ERE-associated
sequence at 21q22.3. This suggestion is supported by the
finding that, in ChIP assays, the variant allele of rs1078272
led to decreased binding of the ERE-associated sequence
to Rad21. An example is shown in Figure 6A, and the
pooled results are shown in Figure 6B. Consistent with this
hypothesis, as shown in Figure 6C, the dose-dependent in-
crease in relative activity in the luciferase reporter assay
caused by Rad21 (left panel) was abolished if this ERE-
associated sequence contained the variant allele of
rs1078272 (right panel).Figure 6 Estrogen response element–associated single-nucleotide po
effects on reporter gene activity regulated by estrogen receptor α, su
activity of the 21q22.3 fragment. The variant allele of rs1078272 decreas
reporter activity. Binding of the 21q22.3 fragment harboring the rs1078272
Rad21 in MCF-7 cells was detected by chromatin immunoprecipitation (IP).
results for the amount of 21q22.3 bound to Rad 21. IgG, Immunoglobulin G
containing the rs1078272 wild-type or variant allele, transfected with vecto
coding for Rad21. The variant allele of rs2839494 decreased estrogen recep
to Rad21 or ERα in MCF-7 cells was detected by chromatin IP. The TFF1 pro
ERα binds, served as the positive control. Real-time qPCR was performed to
expressed as the change in threshold cycle (ΔCT). (E) Binding of the 21q22
(pGL3-803 bp (rs2839494 WT)) or variant allele (pGL3-803 bp (rs2839494 VT
regulatory activity on reporter of 21q22.3 containing the rs2839494 wild-t
or the Rad21-expressing construct (100 or 300 ng) in the presence or abse
disease-free survival (DFS) associated with SNP rs2251362 tagging the est
significantly modified by the genotype of SNP rs959692 tagging the Rad2
for OS (only in ER + patients), this HR remained significant. CI, ConfidenceIt is possible that rs2839494 affected the binding of
this sequence to ERα. This was confirmed by our find-
ings that, in ChIP assays, in addition to binding to
Rad21, this ERE-associated sequence at 21q22.3 could
bind to ERα (Figure 6D) and that the variant allele of
rs2839494 inhibited the binding of this sequence to ERα
(Figure 6E). Furthermore, the increase in Rad21 coactiva-
tion of the ER-regulated activity caused by E2 was reduced
when the wild-type allele of rs2839494 was replaced by
the mutant allele (Figure 6F).
These findings prompted us to assess whether Rad21
plays a role in breast cancer progression, particularly via
the mechanism proposed above. Interestingly, the SNP
rs959692 tagging the Rad21-containing region was not
itself associated with OS and DFS, but it did significantly
modify the association between SNPs in 21q22.3 andlymorphisms at 21q22.3 displaying similar, but not identical,
ggesting Rad21 coactivation of the estrogen receptor–regulated
ed Rad21 binding and Rad21 coactivation of estradiol (E2)-regulated
wild-type (WT) or variant allele (VT) to the transfected Flag-tagged
(A) A typical result and (B) the real-time quantitative PCR (qPCR)
. (C) Regulatory activity of 21q22.3 on reporter in MCF-7 cells
r control (VC) or different amounts (50, 100 or 200 μg) of construct
tor α (ERα) binding and E2-regulated activity. (D) Binding of 21q22.3
moter sequence (shown as TFF1), a well-known sequence to which
measure the amount of bound 21q22.3 fragment. The results are
.3 fragment (that is, pGL3-803 bp) containing the rs2839494 wild-type
)) to ERα in MCF-7 cells is depicted. N.D, No data. (F) Graph depicts the
ype or variant allele in MCF-7 cells transfected with vector control (VC)
nce of 10 nM E2. (G) The hazard ratio (HR) of overall survival (OS) or
rogen response element–associated region at 21q22.3 was
1-containing block. In the subgroup showing a significant HR
interval.
Hsiung et al. Breast Cancer Research 2014, 16:455 Page 10 of 13
http://breast-cancer-research.com/content/16/5/455breast cancer progression (Figure 6G). It is notable that,
after further subgrouping the patients who showed a
significant HR for OS, this HR remained significant in
ER + patients, but not in ER − patients (see ER + and
ER − in Figure 6G), a finding in accordance with the
results of the cell line–based experiments.
Discussion
In the present study, we employed two important ap-
proaches that make it unique from others. First, in con-
trast to most genetic and molecular epidemiological
studies of breast cancer focused on cancer incidence, we
addressed the importance of genetic polymorphisms in
determining breast cancer progression. This issue is
certainly of more translational relevance, and may add
significant prognostic value to the currently used indica-
tors for outcome prediction in breast cancer progression.
Second, we employed a novel methodological approach.
The move from candidate gene association studies to
GWAS has made it possible to explore the etiological
contribution of genetic variants throughout the whole
genome without relying on an a priori hypothesis. As a
result, many novel loci have been identified; the explor-
ation of the genes within these loci should provide in-
formation about which genes and biologic pathways are
associated with complex diseases. With only a very few
notable exceptions, however, the number of detected
causal variants directly responsible for individual GWAS
associations remains small [28]. Most loci identified by
GWAS require further fine-mapping, which usually takes
a long time and a tremendous effort. In the present
study, to provide a partial solution, we used a hybrid
method consisting of candidate gene and genome-wide
approaches. The well-defined roles of the ER during
breast tumorigenesis make it mechanistically reasonable
to assume that polymorphic genetic variants of EREs,
central nodes in the ER pathway, might underlie the
variations seen between patients in their susceptibility
to breast cancer progression. This candidate mechanism
lends critical support to the biological plausibility and
tumorigenic relevance of our findings. In addition, our
genotyping of SNPs on the basis of genome-wide detec-
tion of ERE-associated sequences [8-10] provided us a
unique opportunity to examine real ERα-binding sites
comprehensively. The successful identification of two
ERE-associated SNPs at 21q22.3 using these combined
methods suggests that this is a promising approach which
will benefit from the increase in publicly available genomic
and epigenomic data and bioinformatics platforms and
thus will become more feasible. For example, the EN-
CODE project [26], in which regions of transcription, tran-
scription factor binding, chromatin structure and histone
modification were systematically mapped on a genome-
wide scale, has generated valuable information that can becombined with SNP database data to address genetic sus-
ceptibility to cancer development and progression.
Our reporter gene assay and ChIP results show that
the ERE-associated sequence at 21q22.3 has regulatory
activity and that rs2839494 and rs1078272 in this region
are able to affect the binding of this sequence to ERα
and Rad21, respectively, resulting in a difference in ERα-
activated expression of the reporter gene and suggesting
that Rad21 promotes ERα-regulated transcription. At the
functional level, this is biologically plausible and consistent
with the finding that cohesin, a multisubunit protein com-
plex containing Rad21 that is required for activation of
transcription of Myc by E2, binds to ERα, upon which the
complex binds to an ERE 70-kb upstream of Myc [27].
Even though at the molecular level, alternative models re-
main possible, one of which is that the binding of Rad21
to rs1078272 is through ERα already bound to this SNP or
to the 21q22.3 ERE-associated sequence. However, the
finding reported in ENCODE (shown in Figure 3) clearly
demonstrates that ERα and Rad21 can only bind to spe-
cific and different segments within this 21q22.3 sequence
and that ERα-binding segment does not cover rs1078272.
Furthermore, we conducted an experiment to show that
the effect contributed by the interaction between Rad21
and the rs1078272-containing sequence to promote expres-
sion does not occur indirectly via ERα. In this experiment,
we used a shorter, 414-bp, rs1078272-containing sequence
(that is, the 3′ part of the original 803-bp sequence without
containing any half-ERE site), and we observed the same
result as that shown in Figure 6C, suggesting that the
functional interaction between rs1078272 and Rad21 is
independent of ERα. To confirm this hypothesis in
further studies, researchers can explore the structure of
ERα and Rad21 bound to DNA and examine whether
these two SNPs are located at the protein–DNA interfaces,
affecting protein–DNA interaction. Other mechanisms,
such as higher-order chromatin–protein interactions, can-
not be ruled out.
A more intriguing question is which genes are regulated
by the Rad21-promoted, ERα-activated mechanism sug-
gested by our findings. We comprehensively checked the
region 1,000 kb 5′ to 1,000 kb 3′ of rs2839494. The results
show that, of the 32 genes in this region (Additional file 1:
Figure S1A), 14 have been reported to be involved in vari-
ous tumorigenic mechanisms (Additional file 1: Figure
S1B). Next, on the basis of published information (see, for
example [9,29,30]), public data sets and the RT-qPCR re-
sults in the present study (Additional file 1: Figure S1C),
we examined (1) whether expression of these genes has
been detected in breast tumor or breast cancer cell lines,
(2) whether the expression of these genes is putatively E2-
dependent and (3) whether the proteins encoded by these
genes have a function that is involved in tumor metastasis
(Additional file 1: Figure S1B). On the basis of these
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TMPRSS3 are less likely to be targets of the 21q22.3 ERE-
associated sequence, because the functions of the proteins
encoded by these three genes, as well as clinical observa-
tions, suggest that these proteins play a role as metastasis
promoters [31,32]. This finding is contrary to what we ob-
served in our patients—that the wild-type alleles of the
21q22.3 SNPs caused increased expression of a reporter
gene and were associated with better cancer progression.
Next, although it was found to promote migration and in-
vasion in some cell line models [23], TFF1 remains a pos-
sible target on the basis of the following evidence. TFF1
expression is known to be upregulated by E2 [33] and has
been shown to be an inhibitor of breast cancer metastasis
in an animal model [23]. More importantly, the majority
of the published clinical observations have shown that
TFF1-positive primary breast tumors have a better out-
come profile [23], consistent with our finding that the
wild-type alleles of the SNPs were associated with a de-
creased risk of poor survival. Chromatin conformation
studies (for example, chromosome conformation capture
(3C) [34]) will help determine whether this 21q22.3 ERE
interacts with its target genes and regulates expression by
acting as a long-range regulator. Interestingly, with our
preliminary results detected by 3C, we have identified a
specific region within TFF1 which can form a secondary
structure with the 21q22.3 ERE-associated sequence. This
interaction is more obvious in ER + breast cancer cells
than in ER − cells and can be enhanced by the addition of
E2 (Additional file 2: Figure S2). No such interaction was
detected between the 21q22.3 ERE-associated sequence
and other genes (for example, TMPRSS3) within this re-
gion (unpublished observation).
In the same way that the effect of individual SNPs on
cancer incidence is small, the polymorphic alleles of
ERE-associated SNPs at 21q22.3 predispose carriers to
only a moderately increased risk of poor survival. Thus,
the significance of such SNPs depends not only on the ef-
fect of each SNP alone but also on the interaction between
functionally related alleles of individual SNPs. Our finding
showing that the association between survival and the
21q22.3 SNPs was significantly modified by the SNP tag-
ging ESR1 and the SNP tagging the Rad21-containing
block (Figures 4 and 6G) is in line with this suggestion.
The observed interaction between ERE-associated SNPs
and either the ESR1 SNP or the ER status of the tumor
also provides evidence for the breast tumorigenic rele-
vance of these ERE-associated SNPs.
In the present study, we identified genetic variations at
21q22.3 as important factors in susceptibility to breast
cancer progression. We attempted to address the possibil-
ity of false-positives and the effects of multiple testing by
demonstrating a significant P-value in the permutation
test. Furthermore, the two independent cohorts of patientsyielded consistent results. Together with the functional
experiments in the present study, these associations
suggest that Rad21 promotes the effect of ERα in acti-
vating expression of E2-responsive genes, such as
TFF1, which affects patients’ risk of poor survival. Ex-
pression quantitative trait locus–based analysis to
examine if there is a link between 21q22.3 SNPs and
expression of target genes in human populations is cer-
tainly warranted. More importantly, in our present
study, we started with comprehensive genome-wide
screening for ERE-associated loci that were signifi-
cantly associated with survival status of the patient and
demonstrated that some ERE-associated SNPs showed
a significant association with survival of breast cancer
patients (Figure 2). This suggests that these SNPs are
not just important ones, but the most important ones,
in determining susceptibility to breast cancer progres-
sion. As a result, in our ongoing study, on the basis of
the individual contributions of these significant ERE-
associated SNPs to breast cancer progression, we are
attempting to generate a genetic risk score that can
predict the DFS of our patients. Our preliminary re-
sults show that the inclusion of data for these signifi-
cant ERE-associated SNPs significantly increases the
area under the receiver operating characteristic curve.
This finding might be critical in the development of
new therapeutic and diagnostic approaches for breast
cancer.Conclusions
The promise of personalized medicine, in which the asso-
ciated risk and the course of diseases, as well as the effi-
cacy of treatment protocols, may be predicted on the basis
of a person’s genotype, must been tempered with caution.
Nevertheless, validated molecular tests to assess the pa-
tient’s germline DNA already drive therapeutic decision-
making [7]. On the basis of the well-documented role of
ER in breast cancer progression, we explored whether gen-
etic variations in EREs, the sequences bound by ER to acti-
vate the transcriptional regulation of target genes, are
associated with breast cancer progression. Notably, the
ERE sites genotyped have been shown to bind ERα in vivo
using ChIP-based methods on a genome-wide scale, pro-
viding a unique opportunity to comprehensively examine
putative ERE sites without depending on an a priori hy-
pothesis. The SNPs at the 21q22.3 ERE were found to
affect the binding of ER to ERE, leading to a difference in
ER-regulated transcription, and to be significantly associ-
ated with OS and DFS. These findings support the idea
that functional variants in the ERα-regulating sequence at
21q22.3 are important in determining breast cancer pro-
gression, as well as providing support for a role of ERE
SNPs in breast cancer progression.
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Additional file 1: Figure S1. Genes within the region 1,000 kb 5′ to
1,000 kb 3′ of rs2839494 in 21q22.3. (A) Exons (vertical red lines) and
untranslated regions (blue) of all the genes and untranslated mRNAs
(green) in this region, 14 of which have been reported to be involved in
various tumorigenic mechanisms (B). (C) Estradiol (E2)/estrogen receptor
(ER)–dependent expression of mRNAs for these genes detected by
RT-qPCR in ER-positive (MCF-7) and ER-negative (MDA-MB-231) breast
cancer cell lines. The results are normalized to those for β-actin mRNA.
N.D., not done. *P <0.05 for differences between the conditions with E2
and without E2 in the same cell.
Additional file 2: Figure S2. Chromosome conformation capture (3C)
suggests that the 21q22.3 ERE-associated sequence interacts with TFF1
sequence. (A) Schematic diagrams of the 21q22.3 region containing TFF1,
TMPRSS3, 21q22.3 SNPs and restriction enzyme (EcoRI) sites and the
primers of quantitative PCR (qPCR) used in 3C. (B) Hypothesized model
showing that the 21q22.3 ERE-associated sequence, after binding by the
E2–ERα–p21 complex, forms a secondary structure with a specific region
within TFF1. After restriction enzyme digestion and sequence linking,
qPCR was performed using the forward and reverse primers (that is,
F-primer and R-primer shown in the figure). (C) Relative DNA amounts
detected by qPCR and the interaction between 21q22.3 ERE-associated
sequence and TFF1, measured by amplified qPCR product, are more
significant in ER-positive breast cancer cell lines (that is, MCF-7 and
T47D), than in ER-negative cells (that is, MDA-MB-231, HS578T and
MDA-MB-453) and can be enhanced by the addition of E2 (detected in T47D).
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